Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Curis, Inc. stock logo
CRIS
Curis
$2.32
+6.9%
$2.16
$1.02
$8.29
$22.70M3.6974,589 shs205,653 shs
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$0.50
$0.22
$8.67
$450.52M1.25464,030 shs21,870 shs
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
$3.07
$3.03
$0.88
$6.25
$88.93M-0.81516,108 shsN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Curis, Inc. stock logo
CRIS
Curis
0.00%+0.46%-8.05%+3.33%-68.55%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%-8.93%-77.69%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Curis, Inc. stock logo
CRIS
Curis
3.0891 of 5 stars
3.55.00.00.03.30.00.6
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00632.76% Upside
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00
N/AN/AN/A
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
0.00
N/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ONVO, PTE, NTGN, IDRA, and CRIS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
3/31/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $16.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Curis, Inc. stock logo
CRIS
Curis
$10.91M2.22N/AN/A($0.71) per share-3.27
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/A0.29$0.56 per shareN/A
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
N/AN/AN/AN/A$0.50 per shareN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Curis, Inc. stock logo
CRIS
Curis
-$43.39M-$6.23N/AN/AN/A-376.08%-923.37%-97.14%7/30/2025 (Estimated)
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/A
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A

Latest ONVO, PTE, NTGN, IDRA, and CRIS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
3/31/2025Q4 2024
Curis, Inc. stock logo
CRIS
Curis
-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/A
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Curis, Inc. stock logo
CRIS
Curis
N/A
1.23
1.23
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/A
1.56
1.56
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
0.43
1.58
3.00
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Curis, Inc. stock logo
CRIS
Curis
29.97%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
12.18%
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
54.71%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%

Insider Ownership

CompanyInsider Ownership
Curis, Inc. stock logo
CRIS
Curis
5.70%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
5.05%
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
38.93%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
PolarityTE, Inc. stock logo
PTE
PolarityTE
5.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million9.87 millionNo Data
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
3262.36 million59.21 millionOptionable
Neon Therapeutics Inc stock logo
NTGN
Neon Therapeutics
10228.97 millionN/ANot Optionable
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable

Recent News About These Companies

Regenetp Inc RGTPQ
RegenETP, Inc. (NJT.SG)
PolarityTE Inc. [PTE] Investment Appeal on the Rise
PolarityTE Stock (NASDAQ:PTE), Dividends
Form DEF 14A ENERGY FUELS INC - StreetInsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Curis stock logo

Curis NASDAQ:CRIS

$2.32 +0.15 (+6.91%)
As of 04:00 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Idera Pharmaceuticals stock logo

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Neon Therapeutics stock logo

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.